New Treatments for Hepatitis C

by Columbia Surgery on December 18, 2013

Hep C Article Image (1)Hepatitis C (HCV) is an infection that primarily affects the liver. In the majority of persons, HCV infection becomes chronic and if left untreated can cause numerous outcomes, including cirrhosis and liver cancer. HCV-related end-stage liver disease is the leading cause of liver transplantation in the United States.

Chronic HCV affects nearly four million Americans, and it is estimated that 75 percent of people with chronic infection were born between 1945 and 1965. The risks of cirrhosis and cancer are higher in older individuals and those who have been infected for a longer period of time.

Historically, the backbone of treatment has been a combination of two drugs.

  • Interferon is a drug that activates the immune system to interfere, through different pathways, with production of the virus in infected cells.
  • Ribavirin is a drug that changes the genetic material of the virus and blocks reproduction in cells. Also, it is thought to activate the immune system in order to destroy infected cells.

Prior to 2011, treatment with the combination of these two drugs for 48 weeks cured approximately 40 percent of patients with genotype 1 infection, the most difficult-to-treat form of HCV. However, treatment produced significant side effects (flu-like symptoms, fatigue, depression, anemia, rash), and could complicate other conditions, such as diabetes and thyroid disease.

Poor tolerability forced many patients to discontinue treatment early and lowered their chances of cure. The need for more effective and better tolerated therapies has led researchers and doctors to develop and study classes of drugs that target HCV directly (Direct Acting Antivirals, or DAAs).

  • Protease inhibitors (PIs) include agents like telaprevir, boceprevir and the recently approved simeprevir. Any one of these drugs combined with interferon and ribavirin (triple therapy) improves cure rates and, in some cases, can shorten treatment duration from 48 weeks to 24-28 weeks. Cure rates with triple therapy can be as high as 70 to 80 percent in patients with genotype 1 chronic HCV. However, because the PIs are indicated with interferon and ribavirin, actual cure rates depend on factors such as race/ethnicity and stage of disease. Finally, the PIs have unique side effect profiles and can interact with numerous drugs, causing unwanted side effects.
  • Recent FDA-approval of sofosbuvir, a nucleotide analog, supports treatment for patients with genotype 1 and non-genotype 1 chronic HCV. It will shorten treatment duration to 12 weeks when combined with interferon and ribavirin. Furthermore, for some patients, it will allow for an all oral, non-interferon regimen. Sofosbuvir-containing regimens improve cure rates up to approximately 90 percent.

Clinical trials conducted at Columbia University’s Center for Liver Disease and Transplantation currently study the effectiveness and safety of different interferon-free combinations. These combinations include potent agents that are well tolerated and have fewer interactions with other drugs. When these treatments become available, providers will be able to offer effective and well tolerated therapies to a greater number of patients. The long-term goal of treatment, which is HCV eradication with effective and safe drug combinations, will help to reduce complications from HCV-related liver disease, including cirrhosis and liver cancer, as well as the need for liver transplantation.

{ 5 comments… read them below or add one }

Jacqueline A. F. January 14, 2014 at 10:10 pm

Thank you for this informative article on the New Hep C treatment/cure options. I contracted Hep C from a blood transfusion because of a complicated pregnance in 1982. I opted out of Interferon when offered in 1996 and I don’t regret it. However, I would like to be treated with the New Oral medications when they become available if my prescription plans covers it. Please keep me informed of my options I want to be cured.

Columbia Surgery January 15, 2014 at 11:17 am

Thank you for your interest in this article. Be sure to follow our blog and also our Center for Liver Disease and Transplantation’s website at We try to keep our blog and our website updated with the most recent advancements and treatment options. Best regards and good luck with your treatment.

Robert W January 15, 2014 at 11:16 pm

As a patient of Dr. Micale N.J and also Dr. Robert Brown at Columbia Presbyterian Hospital/Valley Hospital in New Jersey, I am still awaiting word when the oral medication will be available for me Or any treatment Dr. Robert Brown feels will be good for me. I have been so awaiting word about this for quite a while!!
Please keep me informed! I too look forward to a treatment.

Columbia Surgery January 16, 2014 at 10:25 am

Hi Robert,

Thank you for reaching out to us. I am sorry to hear about your frustrations, but I have forwarded your comment to Dr. Robert Brown who would be best able to address it. If you would like to reach out to his office directly, please do not hesitate to call: 212-305-0914. I will reply as soon as I have his response. Thank you for your patience.

Columbia Surgery January 17, 2014 at 3:43 pm

Hi Robert,

I have forwarded your comment to Dr. Brown and if you would like to know your most current options, he encourages you to come back for an appointment to discuss. You may contact his office here at: 212-305-0914. All the best.

Leave a Comment

Previous post:

Next post: